Market opportunities in automated procedures to produce cell therapies
DUBLIN, June 4, 2021 / PRNewswire / – The “Cell Therapy Bioprocessing Market Forecast to 2028 – COVID-19 Impact and Global Analysis by Technology, Cell Type, End User and Geography” the report was added to ResearchAndMarkets.com offer.
Global Cell Therapy Bioprocess Market Expected To Reach $ 30,052.61 million in 2028 11,192.50 million US dollars in 2020. The market is expected to grow with a CAGR of 13.14% from 2020 to 2028.
Cell therapy bioprocessing is a subfield of bioprocess engineering that links cell therapy and bioprocessing (i.e., biopharmaceutical manufacturing). Cell therapy is one of the fastest growing areas of the life sciences. It is the delivery of whole living cells to a patient to treat chronic and rare diseases.
Cell and gene therapy is still at an early stage of development in the biotechnology sector. Although it is a niche area of the biotechnology industry, cell and gene therapy has fostered investment from Development and Contract Manufacturing Organizations (CDMOs) / Contract Manufacturing Organizations (CMOs).
Companies are investing to improve their manufacturing capabilities and deliver world-class therapies to treat chronic diseases. Companies are adopting inorganic and organic strategies such as acquisitions and expansion to expand their cell and gene therapy segment.
Recently, there have been a few cases of companies investing heavily to enter the cell and gene therapy segment. For example, in February 2020, Catalent, Inc. and MaSTherCell Global, Inc. have signed an agreement, in which Catalent, Inc. has agreed to acquire MaSTherCell Global, Inc. for an amount of $ 135 million. It is stated that Catalent, Inc. is well positioned to merge with the R&D capabilities and resources of MaSTherCell Global, Inc. to build its own development and commercial manufacturing facilities.
Likewise, in February 2021, Rentschler Biopharma, a Germany-based CDMO, has expanded its manufacturing capabilities to Cell and Gene Therapy (CGT) Catapult in the UK. Rentschler Biopharma is eager to enter the regenerative medicine segment and start the production of adeno-associated virus (AAV) vectors for cell and gene therapy. Rentschler Biopharma will likely invest an undisclosed amount over the five years and share its expertise and capabilities with CGT Catapult.
Such investments are expected to boost the industry and improve cell therapy bioprocessing in the near future. In addition, in recent years, significant investments have been made by biopharmaceutical companies in the cell and gene therapy segment.
According to the Alliance for Regenerative Medicine (ARM), investments in cell and gene therapy doubled in 2020 compared to 2019 and significantly more than in 2018. Companies around the world have invested US $ 19.9 billion in 2020, while the investments were recorded US $ 13.5 billion in 2018 and US $ 9.8 billion in 2019. Thus, due to heavy investments, the market should flourish in the years to come.
Highlights of the report
- Bioreactor segment held the largest share of the market in 2020, while the genome editing technology segment is expected to register the highest CAGR of 14.5% in the market during the forecast period.
- The stem cell segment held the largest share of the market in 2020, while the same segment is expected to register the highest CAGR of 14.0% in the market during the forecast period.
- The oncology segment held the largest share of the market in 2020, and the orthopedic segment is expected to register the highest CAGR of 14.3% in the market during the forecast period.
Main topics covered:
2. Cell Therapy Bioprocessing Market – Key Points to Remember
3. Research methodology
4. Cell Therapy Bioprocessing Market – Market Landscape
4.2 PEST analysis
4.3 Expert advice
5. Cell Therapy Bioprocess Market – Key Market Dynamics
5.1 Market drivers
5.1.1 Increased investments for the manufacture of cell and gene therapies
5.1.2 Growing Approvals for Cellular Therapies
5.2 Market restrictions
5.2.1 Challenges associated with cell therapy bioprocessing
5.3 Market opportunities
5.3.1 Automated procedures for producing cell therapies
5.4 Future trends
5.4.1 Digital biofabrication
5.5 Impact analysis
6. Cell Therapy Bioprocess Market – Global Analysis
6.1 Global Cell Therapy Bioprocessing Market Forecast and Revenue Analysis
6.2 Global Cell Therapy Bioprocessing Market, By Geography – Forecast and Analysis
6.3 Market positioning of key players
7. Cell Therapy Bioprocessing Market Analysis – By Technology
7.2 Cell Therapy Bioprocessing Market Revenue Share, by Technology (2020 and 2028)
7.6 Centrifugation of the control flow
7.7 Ultrasonic lysis
7.8 Genome editing technology
7.9 Cellular immortalization technology
7.10 Viral vector technology
8. Cell Therapy Bioprocessing Market Analysis – By Cell Type
8.2 Cell Therapy Bioprocessing Market Revenue Share, by Cell Type (2020 and 2028)
8.3 Stem cell
8.4 Immune cell
8.5 Human embryonic stem cell
8.6 Pluripotent stem cell
8.7 Hematopoietic stem cell
9. Cell Therapy Bioprocess Market Analysis – By Indication
9.2 Cell Therapy Bioprocessing Market Revenue Share, by Indication (2020 and 2028)
9.3 Cardiovascular disease (CVD)
9.5 Wound healing
10. Cell Therapy Bioprocessing Market – By End User
10.2 Cell Therapy Bioprocessing Market Revenue Share, by End User (2020 and 2028)
10.3 Hospitals and clinics
10.4 Diagnostic centers
10.5 Regenerative Medicine Centers
10.6 University and research institute
11. Cell Therapy Bioprocessing Market – Geographic Analysis
- Fresenius Kabi SA
- Asahi Kasei Company
- Sartorius SA
- MERCK KGaA
- THERMO FISHER SCIENTIFIQUE INC.
- Corning Incorporated
- Catalent Inc
For more information on this report, visit https://www.researchandmarkets.com/r/e1ig4d
Research and markets
Laura Wood, senior
For EST office hours, call + 1-917-300-0470
For USA / CAN call toll free + 1-800-526-8630
For GMT office hours, call + 353-1-416-8900
US Fax: 646-607-1907
Fax (outside the United States): + 353-1-481-1716
SOURCE Research and Markets